STOCK TITAN

Polyrizon Ltd. (PLRZ) Financials

PLRZ NASDAQ
FY2025 annual
Net Income -$3.3M n/m YoY
EPS (Diluted) -$4.90 YoY not available
Free Cash Flow -$4.5M YoY not available
Operating Cash Flow -$4.5M n/m YoY
Market Cap $22.6M as of Nov 20, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 1.1x on $21.0M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 25, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PLRZ SEC filings page.

This page shows Polyrizon Ltd. (PLRZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Polyrizon Ltd., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
3/6

Polyrizon Ltd. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

Polyrizon Ltd. reported a net loss of $3.3M while operations used $4.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Polyrizon Ltd. reported an operating loss of $6.2M against $370K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$5.6M
YoYn/m

Polyrizon Ltd.'s EBITDA was -$5.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.

Net Income
-$3.3M
YoYn/m

Polyrizon Ltd. reported a net loss of $3.3M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

EPS (Diluted)
-$4.90

Polyrizon Ltd. earned -$4.90 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$4.5M

Polyrizon Ltd. recorded an outflow of $4.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.

Cash & Debt
$1.3M
YoY-48.9%

Polyrizon Ltd. held $1.3M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.

Shares Outstanding
2M

Polyrizon Ltd. had 2M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity
-15.9%
YoY+13.3pp

Polyrizon Ltd.'s ROE was -15.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 13.3 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending
$2.1M
YoY+299.4%

Polyrizon Ltd. invested $2.1M in research and development in fiscal year 2025. This represents an increase of 299.4% from the prior year.

Capital Expenditures
$7K

Polyrizon Ltd. invested $7K in capex in fiscal year 2025, funding long-term assets and infrastructure.

Share Buybacks

Not reported for fiscal year 2025.

PLRZ Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PLRZ annual income statement
MetricFY2520-FFY2420-FFY2320-FFY2220-F
R&D Expenses$2.1M+299.4%$534K+60.8%$332K-4.3%$347K
SG&A Expenses$4.1M+435.9%$768K+153.5%$303K-44.7%$548K
Operating Income-$6.2Mn/m-$1.3Mn/m-$635Kn/m-$895K
EBITDA-$5.6Mn/m-$1.2Mn/m-$631Kn/m-$890K
Interest Expense$370KN/AN/AN/A
Net Income-$3.3Mn/m-$1.5Mn/m-$600Kn/m-$779K
EPS (Basic)-$4.90$805.20+62.9%$494.40$0.60
EPS (Diluted)-$4.90$805.20+62.9%$494.40$0.60
Diluted Shares (Avg)680,3801,994+47.3%1,3541M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

PLRZ Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PLRZ annual balance sheet
MetricFY2520-FFY2420-FFY2320-FFY2220-F
Total Assets$21.4M+286.5%$5.5M+892.3%$559KN/A
Current Assets$12.9M+384.7%$2.7M+4813.0%$54KN/A
Cash & Equivalents$1.3M-48.9%$2.6M+63750.0%$4K-88.9%$36K
Short-Term Investments$0n/m$0-100.0%$37Kn/m$0
Long-Term Investments$0n/m$0n/m$0n/m$0
Total Liabilities$443K+69.7%$261K-65.2%$750KN/A
Current Liabilities$443K+69.7%$261K-48.0%$502KN/A
Non-Current Liabilities$0n/m$0-100.0%$248KN/A
Total Equity$21.0M+297.2%$5.3Mn/m-$191Kn/m-$900K
Retained Earnings-$8.4Mn/m-$5.1Mn/m-$3.5MN/A

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

PLRZ Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PLRZ annual cash flow statement
MetricFY2520-FFY2420-FFY2320-FFY2220-F
Operating Cash Flow-$4.5Mn/m-$1.1Mn/m-$537Kn/m-$1.1M
Depreciation & Amortization$642K+444.1%$118K+2850.0%$4K-20.0%$5K
Stock-Based Compensation$1.3M+2468.6%$51K-49.0%$100K-23.1%$130K
Capital Expenditures$7KN/AN/A$3K
Free Cash Flow-$4.5MN/AN/A-$1.1M
Investing Cash Flow-$16.5M-57113.8%$29KN/A-$3K
Financing Cash Flow$19.8M+440.2%$3.7M+626.3%$505K-22.1%$648K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PLRZ Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PLRZ annual financial ratios
MetricFY2520-FFY2420-FFY2320-FFY2220-F
Return on Equity-15.9%+13.3pp-29.2%N/AN/A
Return on Assets-15.6%+12.3pp-27.9%+79.5pp-107.3%N/A
Current Ratio29.03+18.9x10.16+10.1x0.11N/A
Liabilities-to-Equity0.020.0x0.05N/AN/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Polyrizon Ltd. PLRZ FY2025 N/A -$3.3M N/A $22.6M —
ABVC BioPharma, Inc. ABVC FY2025 $296K -$7.9M N/A $23.4M —
Immutep Limited IMMP FY2026 $16.7M -$54.8M N/A $22.9M 74/100
CervoMed Inc. CRVO FY2025 $4.0M -$27.0M N/A $22.1M 46/100
Evaxion A/S EVAX FY2025 $7.5M -$7.7M N/A $20.8M 86/100
Metagenomi Therapeutics, Inc. MGX FY2025 $25.2M -$87.9M N/A $21.4M 50/100

Frequently Asked Questions

No, Polyrizon Ltd. (PLRZ) reported a net loss of $3.3M in fiscal year 2025.

Polyrizon Ltd. (PLRZ) reported diluted earnings per share of -$4.90 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Polyrizon Ltd. (PLRZ) had EBITDA of -$5.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Polyrizon Ltd. (PLRZ) has a return on equity of -15.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Polyrizon Ltd. (PLRZ) recorded an outflow of $4.5M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Polyrizon Ltd. (PLRZ) recorded an outflow of $4.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Polyrizon Ltd. (PLRZ) had $21.4M in total assets as of fiscal year 2025, including both current and long-term assets.

Polyrizon Ltd. (PLRZ) invested $7K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Polyrizon Ltd. (PLRZ) invested $2.1M in research and development during fiscal year 2025.

Polyrizon Ltd. (PLRZ) had 2M shares outstanding as of fiscal year 2025.

Polyrizon Ltd. (PLRZ) had a current ratio of 29.03 as of fiscal year 2025, which is generally considered healthy.

Polyrizon Ltd. (PLRZ) had a liabilities-to-equity ratio of 0.02 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Polyrizon Ltd. (PLRZ) had a return on assets of -15.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Polyrizon Ltd. (PLRZ) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $22.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Polyrizon Ltd. (PLRZ) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $22.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Polyrizon Ltd. (PLRZ) held $1.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.5M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Polyrizon Ltd. (PLRZ) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Polyrizon Ltd. (PLRZ) reported a net loss of $3.3M while operations used $4.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Polyrizon Ltd. (PLRZ) reported an operating loss of $6.2M against $370K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top